Anti-Rickettsia, LPS (RICK-5621)

Formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

This monoclonal antibody is purified by protein A chromatography or sequential differential precipitations.

This purified antibody is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2-8°C Wet Ice

Anti-Rickettsia (Clone RICK-5621) is specific for the LPS of 24 species in the Spotted Fever Group (R. felis weakly) or Rickettsia. It is non-reactive against R. typhi and R. prowazekii.

The Rickettsia Spotted Fever Group (SFG) is a subset of the Rickettsia genus that includes several species of bacteria responsible for causing Spotted Fever diseases in humans. These diseases are primarily transmitted through tick bites and are prevalent in various regions worldwide. Notable members of this group include Rickettsia rickettsii, the causative agent of Rocky Mountain Spotted Fever, Rickettsia conorii causing Mediterranean Spotted Fever, and Rickettsia parkeri causing a mild form of Spotted Fever. Spotted Fever diseases typically present with symptoms such as fever, headache, muscle aches, and a characteristic spotted rash. These infections can be severe and even life-threatening if not promptly diagnosed and treated with appropriate antibiotics. Effective prevention and control efforts focus on tick avoidance measures and early recognition of symptoms to reduce the incidence and impact of Rickettsia Spotted Fever group infections on public health. Laboratory diagnosis involves demonstration of a 4x rise in IgG-specific antibody titer by indirect immunofluorescence antibody assay (IFA) among others.

1. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne Diseases (DVBD), Link